Literature DB >> 12016098

Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease.

Sarah V Culpitt1, Carmen de Matos, Richard E Russell, Louise E Donnelly, Duncan F Rogers, Peter J Barnes.   

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by a neutrophilic airway inflammation that can be demonstrated by examination of induced sputum. Theophylline has antiinflammatory effects in asthma, and in the present study we investigated whether a similar effect occurs in COPD patients treated with low doses of theophylline. Twenty-five patients with COPD were treated with theophylline (plasma level of 9-11 mg/L) for 4 weeks in a placebo-controlled, randomized, double-blind crossover study. Theophylline was well tolerated. Induced sputum inflammatory cells, neutrophils, interleukin-8, myeloperoxidase, and lactoferrin were all significantly reduced by about 22% by theophylline. Neutrophils from subjects treated with theophylline showed reduced chemotaxis to N-formyl-met-leu-phe (approximately 28%) and interleukin-8 (approximately 60%). Neutrophils from a healthy donor showed reduced chemotaxis (approximately 30%) to induced sputum samples obtained during theophylline treatment. These results suggest that theophylline has antiinflammatory properties that may be useful in the long-term treatment of COPD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12016098     DOI: 10.1164/rccm.2105106

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

1.  Theophylline for COPD.

Authors:  P J Barnes
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

2.  Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma.

Authors:  Hyung-Geun Moon; You-Sun Kim; Jun-Pyo Choi; Dong-Sic Choi; Chang Min Yoon; Seong Gyu Jeon; Yong Song Gho; Yoon-Keun Kim
Journal:  Exp Mol Med       Date:  2010-01-31       Impact factor: 8.718

3.  Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.

Authors:  Chun-Hua Wang; Horng-Chyuan Lin; Chien-Huang Lin; Chih-Teng Yu; Su-Ling Liu; Kuo-Hsiung Huang; Kian Fan Chung; Han-Pin Kuo
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

4.  Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline.

Authors:  T Hirano; T Yamagata; M Gohda; Y Yamagata; T Ichikawa; S Yanagisawa; K Ueshima; K Akamatsu; M Nakanishi; K Matsunaga; Y Minakata; M Ichinose
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

5.  Comparative study on the efficacy of tiotropium bromide inhalation and oral doxofylline treatment of moderate to severe stable chronic obstructive pulmonary disease.

Authors:  Tao Wang; Guangwei Luo; Yi Hu; Fajiu Li; Jing Ma; Jianmiao Wang; Peng Zuo; Weining Xiong; Xiansheng Liu; Jianping Zhao; Shengdao Xiong; Zhenxiang Zhang; Chenghong Li; Su Zhao; Jiemin Sun; Yongjian Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

6.  Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

Authors:  M Profita; G Chiappara; F Mirabella; R Di Giorgi; L Chimenti; G Costanzo; L Riccobono; V Bellia; J Bousquet; A M Vignola
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 7.  Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.

Authors:  Graeme P Currie; Claire A Butler; Wendy J Anderson; Chris Skinner
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

Review 8.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Authors:  Mark A Giembycz; Stephen K Field
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

Review 9.  Chronic obstructive pulmonary disease: an update on diagnosis and management issues in older adults.

Authors:  Shoab A Nazir; Marcia L Erbland
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 10.  Optimising treatment for COPD--new strategies for combination therapy.

Authors:  T Welte
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.